In studies where all patients in the general population presenting with dyspepsia were referred for endoscopy, the prevalence of pathology was:
|
|
- Amy Edwards
- 6 years ago
- Views:
Transcription
1 There is so much we don t know in medicine that could make a difference, and often we focus on the big things, and the little things get fgotten. To highlight some smaller but imptant issues, we ve put together a series of pearls that the Red Whale found at the bottom of the ocean of knowledge! Dyspepsia Doc, you ve got to do something about my guts every time I go out with my mates I m doubled up afterwards I ve tried taking ibuprofen befe the beers, but it just doesn t help! This common condition costs the NHS 1 billion annually affected individuals have a nmal life expectancy but an impaired quality of life. It was recently reviewed in the BMJ (BMJ 2013;347:f5059). Definitions and aetiology Dyspepsia affects 20 40% of the wld s population! Dyspepsia = epigastric pain discomft f 3m me in the absence of predominant heartburn regurgitation. Gastro-oesophageal reflux disease (GORD) = discomft f 3m where heartburn regurgitation are dominant. Dyspepsia is associated with: NSAID use H. pyli infection Anxiety Overlaps with IBS and GORD. The majity of patients presenting with dyspepsia in primary care can be safely managed with lifestyle advice and if necessary empirical treatment with acid suppression. However, our first job is to decide which patients need further investigation. Who needs H. pyli testing? NICE guidelines (NICE 2005, CG17) offer GPs a choice of treat then test test then treat and suggest they are equally effective. However, the Health Protection Agency remind us that the prevalence of H. pyli is falling in developed countries and is less than 15% in most areas of the UK they recommend we should treat empirically with acid suppression first in most cases and test the following groups: Patients with dyspepsia that is unresponsive to lifestyle change and 1m of PPI. Patients with a past histy of peptic duodenal ulcer who have never been tested. Patients starting long-term NSAIDs. Unexplained iron deficiency anaemia, idiopathic thrombocytopenic purpura and vitamin B12 deficiency. Which H. pyli test should be used? The urea breath test and stool antigen tests are the most accurate because they detect current infection. The following caveats exist: Do not perfm the urea breath test stool antigen test within 2w of taking a PPI within 4w of taking antibiotics they may lead to false negative results. Blood serology is good at ruling out H. pyli infection, but cannot differentiate between current and past infection. It is most useful in the context of acute GI bleed where you may not want to stop the PPI f the test. Who needs referral f endoscopy? In studies where all patients in the general population presenting with dyspepsia were referred f endoscopy, the prevalence of pathology was: Erosive oesophagitis 13% Peptic ulcer disease 8% Gastro-oesophageal cancer 0.3% No clinically significant finding (functional dyspepsia) 70 80%. In the UK, we should refer patients presenting with dyspepsia and any of the following red flag features f urgent endoscopy: Age 55y with new onset dyspepsia. Chronic gastrointestinal bleeding. Dysphagia. Progressive unintentional weight loss. Persistent vomiting. Iron deficiency anaemia. Epigastric mass. In reality, we often end up referring patients f endoscopy when first and second line treatments have failed - this is sometimes necessary to reassure both patient and doct and allow us to move on to consider alternative strategies!
2 Treatment options Having decided which patients need further investigations, you can get on and try treatment in the rest! 1. Offer empirical acid suppression therapy f 4w then try to stop: Often we reach straight f the PPIs but the Diamond trial challenged this (Lancet 2009;373:215). It was a primary care based study that randomised 650 patients presenting with dyspepsia to: Step up therapy (antacid then H2RA then PPI) Step down therapy (PPI then H2RA then antacid). Each step lasted 4w and patients progressed between steps accding to symptom control. Both treatment regimens were equally effective but costs were significantly lower with the step up approach let s offer patients a choice! 2. If acid suppression is inadequate to manage symptoms, test and treat f H. pyli: Patients with a positive H. pyli test should be offered eradication treatment as the NNTs f treatment are impressive: NNT = 2 to prevent a relapse of duodenal ulcer. NNT = 3 to prevent relapse of gastric ulcer. NNT = 14 to improve symptoms in functional dyspepsia. The following regimens are recommended by the HPA based on current UK sensitivities (but follow local guidance if it exists because some areas in the UK have high clarithromycin resistance). When choosing antibiotics, take into account previous antibiotic prescriptions in the past 12m because a script f clarithromycin metronidazole f any other reason in the past year makes resistance me likely this is not the case f amoxicillin. First-line 7 day triple therapy regimens PPI twice daily (Omeprazole 20mg twice daily Lansoprazole 30mg twice daily) PLUS Amoxicillin 1g twice daily and Clarithromycin 500mg twice daily Metronidazole 400mg twice daily and Clarithromycin 250mg twice daily Amoxicillin 1g twice daily and metronidazole 400mg twice daily Second line 14 day quadruple therapy regimen PPI twice daily (Omeprazole 20mg twice daily Lansoprazole 30mg twice daily) PLUS tripotassium dicitratobismuthate 240mg twice daily PLUS
3 2 antibiotics (pick those not previously used) Tetracycline 500mg four times daily Metronidazole 400mg twice daily Clarithromycin 500mg twice daily Amoxicillin 1g twice daily The majity of patients do not need a test of cure. If severe symptoms persist, wait 4 8w after completion of eradication treatment and use the breath test stool antigen test (serology can remain positive f up to a year). 3. Prokinetic drugs These may be helpful in functional dyspepsia especially if patients rept symptoms of delayed gastric emptying. A Cochrane review looked at 24 placebo-controlled trials of prokinetics and found an NNT = 6. However, the majity of these trials used cisapride which has now been withdrawn because of concerns about cardiac safety. There was only one trial including domperidone and no RCTs f metoclopramide. In addition the MHRA has recently raised concerns about the safety profile of domperidone and metoclopramide see drug dilemma below! 4. Antidepressants F functional dyspepsia, low dose tricyclics (amitriptyline and imipramine) have been shown to be modestly effective compared with placebo SSRIs have not. What about sequential H. pyli eradication regimens? We have previously taught about the potential benefits of higher H. pyli eradication rates using a sequential eradication regimen comprising: Amoxicillin 1g twice daily + PPI twice daily f 5d then Clarithromycin 500mg twice daily + Metronidazole 400mg twice daily +PPI twice daily f a further 5d. A recent BMJ meta-analysis looked at this issue incpating 46 RCTs, none of which were perfmed in the UK and most of which were perfmed in countries with higher clarithromycin and metronidazole resistance that we see in the UK (BMJ 2013;347:f4587). They found that: Sequential therapy had superi eradication rates to standard 7d triple therapy (86.5% vs. 71%). Sequential therapy had similar eradication rates to 10d, 14d and bismuth-containing treatment regimens. Should this change our practice? No. In 2012, the leading gastroenterologists of the wld met and produced guidelines on H. pyli testing and treatment Maastricht IV (Gut 2012;61:646). They concluded on the basis of current evidence that, in countries with low clarithromycin resistance (<20%), standard triple therapy should be first line and bismuth-containing quadruple therapy should be second line because of simpler regimes, lower likelihood of promoting resistance and better concdance. Clarithromycin resistance rates in the UK are currently between 4 and 11% highest in London (HPA). This is why the regimens in the box above are recommended. However, this may change!
4 Drug Dilemma: Prokinetics Prokinetics are commonly used as add-on treatments in functional dyspepsia. The majity of the trials which showed benefit used cisapride which was withdrawn from the market some years ago because of concerns about cardiac safety. It was replaced clinically with domperidone and metoclopramide. However in the last 12 months the MHRA have raised concerned and suggested new restrictions be placed on both of these drugs: Metoclopramide (MHRA Drug Safety Update August 2013) This warning followed a French review of all the literature and safety data regarding the potential neurological side effects of metoclopramide which have been known f a long time sht term extra-pyramidal disders and tardive dyskinesias. It concluded that the harms outweighed the benefits in long term high dose use. The risks were higher in children than adults. They made the following recommendations: Indication: Adults: f the symptomatic management of nausea and vomiting including that occurring post-operatively, associated with chemotherapy with migraine. Children: as a second line agent only f the management of chemotherapy surgical nausea and vomiting. Contraindicated in under 1 year olds. They do not mention any license indication f use in dyspepsia (and note there are no RCTs of metoclopramide used in this context). Duration and dosage Prescribe f sht term use only (maximum 5 days recommended). Maximum dose f adults is 30mg/24 hour period usually 10mg tds. Maximum dose f children 1 year older is mg kg per dose (maximum 0.5mg/kg/24 hours). Domperidone (MHRA Drug Safety Update May 2014) Concerns have been expressed about the risk of cardiac arrhythmias associated with domperidone after a review of all published and unpublished safety date. It has been found to be associated with an increased risk of QTc prolongation, tsades de pointes and ventricular tachycardia. This has been found to be particularly the case at high doses (>30mg daily) and use f prolonged durations. Harms were also me common in those aged >60 years F this reason the MHRA are specifically recommending: Domperidone should no longer be used f bloating, heartburn dyspepsia because there is no good evidence it is beneficial and the harms may outweigh the benefits in this situation. It is contraindicated in individuals where cardiac conduction is could be impaired in those with heart failure those taking other QTc prolonging drugs/ potent CYP3A4 inhibits e.g. fluconazole, itraconazole (your computer prescribing system should warn of these interactions). The benefits may outweigh the harms f nausea and vomiting and if used: It should be prescribed at the lowest dose (maximum 30mg daily when given ally 30mg twice daily when given as supposities) and f the shtest duration possible (usually <7 days). In children under 12 years, the maximum daily recommended dose is 0.75mg/kg as 3 divided doses over 24 hours. What does this mean in practice? The MHRA release suggested we should review these medications at the next routine review. It would be sensible to do a search f all patients with metoclopramide and domperidone on repeat prescription and have a plan of how and when we will review this. If the indication f use has been dyspepsia, we can consider whether it is still needed and if so consider alternatives as detailed above. F some patients this may require referral advice from gastroenterology. This means there are no prokinetics licensed in the UK f the management of GORD functional dyspepsia. Summary: Dyspepsia Dyspepsia is common and most patients can be treated on the basis of histy alone. Refer patients with red flags f endoscopy. Test f H. pyli if there is initial treatment failure, a histy of peptic ulcers an intention to start long-term NSAIDs. Use the urea breath test stool antigen test. Pick eradication regimen accding to local sensitivities and the patient s personal antibiotic histy. If despite this patients remain symptomatic with functional dyspepsia, consider amitriptyline. The MHRA have expressed safety concerns about domperidone and metoclopramide and no longer recommend their use f functional dyspepsia. Identify all repeat prescriptions f domperidone and metoclopramide what is the indication? Review with the patient at the next medication review and develop an alternative management plan.
5 Focussed Learning Activity: Dyspepsia Read the section above. Write brief notes on your key learning points don t regurgitate the section, focus on the things you did not know/want to remember. This might include: A reminder of definitions Groups f whom we should consider H pyli testing Red flags f urgent endoscopy Treatment options Local H pyli sensitivities - you might need to ask The prokinetics drug dilemma Other learning points Think about your current practice regarding investigation, referral, empirical and eradication treatment in the light of what you have learned reading this section. Write a brief reflective piece on your current management, what guidance rationale you have based this on in the past, and how you might change your practice in the future.
6 Run a search f any patients with repeat prescriptions f domperidone metoclopramide. Review the indication f which these drugs have been prescribed. Consider what action you will take f those not consistent with the MHRA recommendations. Make brief notes of your findings and any actions you have taken. Thinking back over this learning activity ( the parts you have found useful to complete), what is the key learning point? What will you do differently?
7 The Red Whale GP Update Course The one day course f GPs and GP Registrars, by GPs. (We think it s the most fun you can have earning CPD credits!) The GP Update Course brings you up to speed with all the latest issues, guidelines and research. Run entirely by GPs, we trawl through all the literature and pick out the things that are relevant to everyday general practice and present it in a lively and entertaining way. If you book on this course you will get: The GP Update Handbook - comprehensive and fully referenced covering all the most recent research and guidelines pertinent to primary care but interpreted f real life general practice. 12 months FREE access to - our revitalised, fully searchable and most comprehensive online reference source ever! The GP Update Handbook Online - twice the contents of the paper version and you can earn credits f every page you read at the click of a button! Focused Learning Activities - activity ideas that amount to much me than 50 hours of CPD credits and me imptantly that will really impact on patient care - not just a series of tick box exercises. The GP Update Course is completely free from pharmaceutical company sponsship. This means that you can be totally reassured that there will be no biasing of the infmation presented to you and that there will be no reps there on the day! Spring/Summer 2015 dates: London - Friday March 6 London - Saturday March 7 Leeds - Thursday March 12 Oxfd - Friday March 13 Birmingham - Saturday March 14 Bristol - Wednesday May 13 Exeter - Thursday May 14 London - Friday May 15 London - Saturday May 16 Belfast - Wednesday May 20 Newcastle - Wednesday June 3 Sheffield - Thursday June 4 Manchester - Friday June 5 Birmingham - Saturday June 6 Nwich - Wednesday June 10 London - Thursday June 11 Chelmsfd - Wednesday June 24 GPs 195, ST1, 2 & 3 and Nurses 150. F me details see We make every efft to ensure the infmation in these pages is accurate and crect at the date of publication, but it is of necessity of a brief and general nature, and this should not replace your own good clinical judgement, be regarded as a substitute f taking professional advice in appropriate circumstances. In particular check drug doses, side effects and interactions with the British National Fmulary. Save insofar as any such liability cannot be excluded at law, we do not accept any liability f loss of any type caused by reliance on the infmation in these pages. GP Update Limited
Management of dyspepsia and of Helicobacter pylori infection
Management of dyspepsia and of Helicobacter pylori infection The University of Nottingham John Atherton Wolfson Digestive Diseases Centre University of Nottingham, UK Community management of dyspepsia
More informationQOF (England): clinical indicators
QOF 2015 16 (England): clinical indicators Here is a quick summary of the planned changes for QOF in England for 2015 16. This covers only the clinical aspects of QOF, as you might need them in the consultation,
More informationGuidelines for the Management of Dyspepsia and GORD. Gastroenterology/ Acute Adult Governance. Drugs and Therapeutics Committee
Guidelines for the Management of Dyspepsia and GORD Document type: Version: 3.0 Author (name): Author (designation): Validated by Prescribing Dr. G. Lipscomb Date validated October 2015 Ratified by: Date
More informationMANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Routine endoscopic investigation of patients of any age, presenting with dyspepsia
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA o Patients of any age with ALARM signs should be referred through the 2-week referral system o Routine endoscopic investigation
More informationManagement of Dyspepsia
MPharm Programme Management of Dyspepsia Slide 1 of 28 Learning Objectives Understand the principles and wider implications underpinning evidence based therapeutics in the key clinical specialities Objectively
More informationManagement of dyspepsia in adults in primary care
Dyspepsia Management of dyspepsia in adults in primary care June 2005. The recommendations on referral for endoscopy in this NICE guideline have been amended in line with the recommendation in the NICE
More informationJune By: Reza Gholami
ACG/CAG guideline on Management of Dyspepsia June 2017 By: Reza Gholami DEFINITION OF DYSPEPSIA AND SCOPE OF THE GUIDELINE Dyspepsia was originally defined as any symptoms referable to the upper gastrointestinal
More informationGASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA
GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA MANAGEMENT Dyspepsia refers to a spectrum of usually intermittent upper gastrointestinal symptoms, including epigastric pain and heartburn. For the majority
More informationThe PPI Doesn t Work, Now What? PPI Non-responsive Dyspepsia. Disclosures
The PPI Doesn t Work, Now What? PPI Non-responsive Dyspepsia Lana Bistritz MD FRCPC Royal Alexandra Hospital GI Update 2016 Disclosures I have no relevant financial disclosures I will be discussing off
More informationClinical guideline Published: 3 September 2014 nice.org.uk/guidance/cg184
Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Clinical guideline Published: 3 September 2014 nice.org.uk/guidance/cg184 NICE 2014. All rights reserved. Last modified
More informationPRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW
PRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY Dyspepsia refers to a broad range of symptoms related
More informationTreatment of Helicobacter pylori Infection
Treatment of Helicobacter pylori Infection Epidemiology of H. pylori infection (North America) Which are the high risk groups? Epidemiology of H. pylori infection (North America) Which are the high risk
More informationProton Pump Inhibitors Drug Class Prior Authorization Protocol
Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review
More informationCataract: Tamsulosin and cataract operations
There is so much we don't know in medicine that could make a difference, and often we focus on the big things, and the little things get forgotten. To highlight some smaller but important issues, we've
More informationHigh use of maintenance therapy after triple therapy regimes in Ireland
High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity
More informationIndigestion (dyspepsia)
Commissioning pathways Indigestion (dyspepsia) Supplementary information to be read in conjunction with the pathway Reference Supplementary Information 1.1 Symptom Description Annual incidence 40%. Prevalence
More information6/25/ % 20% 50% 19% Functional Dyspepsia Peptic Ulcer GERD Cancer Other
Peptic Ulcer Disease and Dyspepsia John M. Inadomi, MD Professor of Medicine UCSF Chief, Clinical Gastroenterology San Francisco General Hospital Case History 49 y/o woman complains of several months of
More informationIf a drug trigger is suspected, stop the offending drug as this may reduce the risk of relapse.
There is so much we don't know in medicine that could make a difference, and often we focus on the big things, and the little things get forgotten. To highlight some smaller but important issues, we've
More informationCOMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées
OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 5 March 2007 Current Practice Analysis Report for the Prescribing and Use of Proton Pump Inhibitors (PPIs) Supporting Informed Decisions À l appui des décisions
More informationDyspepsia: alarm symptoms, investigation and management
Drug review Dyspepsia Dyspepsia: alarm symptoms, investigation and management SPL Steven Fong MRCP and Jason Dunn PhD, MRCP Dyspepsia is a common symptom and the priority is to identify alarm signals that
More informationInternal Clinical Guidelines Team
Internal Clinical Guidelines Team Full Guideline Dyspepsia and gastrooesophageal reflux disease: investigation and management of dyspepsia, symptoms suggestive of gastro-oesophageal reflux disease, or
More informationGASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali
GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers
More informationWhat is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori?
What is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori? Sequential Therapy Versus Standard Triple- Drug Therapy for Helicobacter pylori
More informationFaecal immunochemical testing and colorectal cancer
There is so much we don't know in medicine that could make a difference, and often we focus on the big things, and the little things get forgotten. To highlight some smaller but important issues, we've
More informationBarrett s Oesophagus Information Leaflet THE DIGESTIVE SYSTEM. gutscharity.org.
THE DIGESTIVE SYSTEM http://healthfavo.com/digestive-system-for-kids.html This factsheet is about Barrett s Oesophagus Barrett s Oesophagus is the term used for a pre-cancerous condition where the normal
More informationACG Clinical Guideline: Treatment of Helicobacter pylori Infection
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection William D. Chey, MD, FACG 1, Grigorios I. Leontiadis, MD, PhD 2, Colin W. Howden, MD, FACG 3 and Steven F. Moss, MD, FACG 4 1 Division
More informationPeptic ulcer disease Disorders of the esophagus
Peptic ulcer disease Disorders of the esophagus Peptic ulcer disease Burning epigastric pain Exacerbated by fasting Improved with meals Ulcer: disruption of mucosal integrity >5 mm in size, with depth
More informationOutline. Definition (s) Epidemiology Pathophysiology Management With an emphasis on recent developments
Chronic Dyspepsia Eamonn M M Quigley MD FRCP FACP MACG FRCPI Lynda K and David M Underwood Center for Digestive Disorders Houston Methodist Hospital Houston, Texas Outline Definition (s) Epidemiology Pathophysiology
More informationSetting The setting was primary care. The economic study was conducted in Canada.
Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment - Helicobacter pylori positive (CADET-Hp) randomised controlled
More informationHelicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.
An Update on Helicobacter pylori and Its Treatment Trenika Mitchell, PharmD, BCPS Clinical Assistant Professor University of Kentucky College of Pharmacy October 18, 2008 Objectives Review the epidemiology
More informationConcise guide to management of reflux disease in primary care
Drug review GORD Concise guide to management of reflux disease in primary care Kumar Kanti Basu BSc, FRCP Reflux is a common disorder often aggravated by lifestyle and other medications. Our Drug review
More informationPEPTIC ULCER DISEASE JOHN R SALTZMAN, MD. Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School
PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School No disclosures Disclosures Overview Causes of peptic ulcer disease
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: helicobacter_pylori_testing 01/01/2019 N/A 01/01/2020 01/01/2019 Policy Effective April 1, 2019 Description
More informationQUICK QUERIES. Topical Questions, Sound Answers
QUICK QUERIES Topical Questions, Sound Answers Dyspepsia: An Evidence-Based Approach Alan B. R. Thomson, MD, PhD, FRCPC, FACP, FACG Presented at the University of Alberta s Medical Grand Rounds, University
More informationHelicobacter Pylori Testing HELICOBACTER PYLORI TESTING HS-131. Policy Number: HS-131. Original Effective Date: 9/17/2009
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationScottish Medicines Consortium
Scottish Medicines Consortium ketoprofen/, 100mg/20mg; 200mg/20mg modified release capsules (Axorid ) No. (606/10) Meda Pharmaceuticals 05 February 2010 The Scottish Medicines Consortium (SMC) has completed
More informationThe significance of Helicobacter pylori in the approach of dyspepsia in primary care Arents, Nicolaas Lodevikus Augustinus
University of Groningen The significance of Helicobacter pylori in the approach of dyspepsia in primary care Arents, Nicolaas Lodevikus Augustinus IMPORTANT NOTE: You are advised to consult the publisher's
More informationWhat Is Peptic Ulcer Disease?
What Is Peptic Ulcer Disease? Peptic ulcer disease is when painful sores form in the lining of the stomach, duodenum (start of the small intestine) or bowels. An ulcer can cause belly pain and, in some
More informationRpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives
Esomeprazole 20mg Name, Restriction, Manner of esomeprazole 20 mg enteric tablet, 30 (8886Q) (029W) Gastric ulcer Peptic ulcer Treatment Phase: Initial treatment The therapy must be for initial treatment
More informationReflux of gastric contents, particularly acid, into the esophagus
Heartburn Reflux of gastric contents, particularly acid, into the esophagus Patient assessment with GERD 1-signs and symptoms The hallmark of typical symptom of GERD is heartburn (restrosternal),acid regurgitation,
More informationEuropean Medicines Agency recommends changes to the use of metoclopramide
20 December 2013 EMA/13239/2014 Corr. 1 European Medicines Agency recommends changes to the use of metoclopramide Changes aim mainly to reduce the risk of neurological side effects On 24 October the European
More informationNumber of studies. Endoscopic finding. Number of subjects. Pooled prevalence 95% CI
Clinical Approach to the Patient t with Dyspepsia William D. Chey, MD, FACG Professor of Medicine University of Michigan Prevalence of Endoscopic Findings in Individuals with Dyspepsia Systematic Review
More informationNon-Ulcer Dyspepsia: what is it? What can we do with these patients? Overview. Dyspepsia Definition. Functional Dyspepsia. Dyspepsia the Basics
Non-Ulcer : what is it? What can we do with these patients? Temporal Changes and Geographic Variations in Developing Peptic Ulcer Disease Gastric Cancer 1900 Eamonn M M Quigley MD FACG Alimentary Pharmabiotic
More informationAffects 3.5% of pregnancies in the UK. Risk of developing type 2 diabetes is estimated at between 2 and 70%(!!!) depending on the population tested.
There is so much we don't know in medicine that could make a difference, and often we focus on the big things, and the little things get forgotten. To highlight some smaller but important issues, we've
More informationSetting The setting was primary care. The economic analysis was conducted in Glasgow, UK.
Helicobacter pylori eradication for peptic ulceration: an observational study in a Scottish primary care setting Forrest E H, MacKenzie J F, Stuart R C, Morris A J Record Status This is a critical abstract
More informationIdentifying patients who may benefit from stepping down PPI treatment
CLINICAL AUDIT Identifying patients who may benefit from stepping down PPI treatment Valid to January 2024 bpac nz better medicin e This audit identifies patients who are prescribed the proton pump inhibitor
More informationPLANNING COMMITTEE. Seek simplicity, and mistrust it. Alfred North Whitehead
PLANNING COMMITTEE 1. Content Experts Clinical experts Desmond Leddin MB FRCPC, Head, Division of Gastroenterology, Dalhousie University Drug evaluation pharmacist Pam McLean-Veysey BScPharm, Drug Evaluation
More informationCHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS. 1. Which of the following is not a common cause of peptic ulcer disease (PUD)?
CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS 1. Which of the following is not a common cause of peptic ulcer disease (PUD)? A. Chronic alcohol ingestion B. Nonsteroidal antiinflammatory
More informationCOMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées
OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 6 March 2007 Gap Analysis Report for the Prescribing and Use of Proton Pump Inhibitors (PPIs) Supporting Informed Decisions À l appui des décisions éclairées
More informationPrevpac Pylera Omeclamox-Pak
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.21 Subject: -Pak Page: 1 of 5 Last Review Date: September 20, 2018 -Pak Description (lansoprazole,
More informationA Heaney, J S A Collins, RGPWatson, R J McFarland, K B Bamford, T C K Tham
186 Royal Victoria Hospital, Belfast, A Heaney J S A Collins Department of Medicine, Queen s University, Belfast, RGPWatson Ulster Hospital, Dundonald, R J McFarland T C K Tham Department of Microbiology
More informationSurveillance proposal consultation document
Surveillance proposal consultation document 2018 surveillance of Gastro-oesophageal reflux disease in children and young people: diagnosis and management (NICE guideline NG1) Proposed surveillance decision
More informationNeuropathic pain can be tricky to diagnose and manage because its aetiology can be very varied and patients may describe it in many different ways.
There is so much we don't know in medicine that could make a difference, and often we focus on the big things, and the little things get forgotten. To highlight some smaller but important issues, we've
More informationAspirin: what do we know so far? What is new this week?
Aspirin: what do we know so far? What is new this week? This article discusses the data published this week on the harms of low-dose aspirin, and particularly the harms with increasing age. It also looks
More informationALL YOU NEED TO KNOW ABOUT INDIGESTION FUNDING RESEARCH INTO DISEASES OF THE GUT, LIVER & PANCREAS
ALL YOU NEED TO KNOW ABOUT INDIGESTION FUNDING RESEARCH INTO DISEASES OF THE GUT, LIVER & PANCREAS THIS FACTSHEET IS ABOUT INDIGESTION Indigestion (also known as dyspepsia) is a term used to describe unpleasant
More informationSuperficial thrombophlebitis
There is so much we don't know in medicine that could make a difference, and often we focus on the big things, and the little things get forgotten. To highlight some smaller but important issues, we've
More informationDYSPEPSIA Dyspepsia indigestion during or after eating Full Heat, burning or pain Note: one of every four people
What Is Dyspepsia? Dyspepsia, also known as indigestion, can have multiple symptoms. Feelings of indigestion happen during or after eating. If you have indigestion you might feel: Full during a meal. Painful
More informationOne-third of adults experience pain or discomfort in
GASTROENTEROLOGY 2002;122:1270 1285 Dyspepsia Management in Primary Care: A Decision Analysis of Competing Strategies BRENNAN M. R. SPIEGEL,* NIMISH B. VAKIL, and JOSHUA J. OFMAN*, *Department of Medicine
More informationApproaches to uninvestigated dyspepsia
iv42 DYSPEPSIA MANAGEMENT Approaches to uninvestigated dyspepsia R H Jones... Uninvestigated dyspepsia refers to patients with new or recurrent dyspeptic symptoms in whom no investigations have previously
More informationOmeprazole 10mg. Name, Restriction, Manner of administration and form OMEPRAZOLE omeprazole 10 mg enteric tablet, 30 (8332M) Max. Qty.
Omeprazole 10mg Name, Restriction, Manner of administration and form omeprazole 10 mg enteric tablet, 30 (8332M) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form omeprazole
More informationDyspepsia is a problem commonly seen by primary
Concise Review for Clinicians Nonulcer Dyspepsia: What It Is and What It Is Not G. RICHARD LOCKE III, MD Nonulcer dyspepsiais a description of persistent or recurrent upper abdominal pain or discomfort
More informationStudy population The study population comprised hypothetical patients with gastric and duodenal ulcer.
Evaluation of the cost-effectiveness of Helicobacter pylori eradication triple therapy vs. conventional therapy for ulcers in Japan Ikeda S, Tamamuro T, Hamashima C, Asaka M Record Status This is a critical
More information11/19/2012. Comparison between PPIs G CELL. Risk ratio (95% CI) Patient subgroup. gastrin. S-form of omeprazole. Acid sensitive. coated.
REGULATION OF GASTRIC ACID SECRETION Comparison between PPIs Omeprazole Lansoprazole Rabeprazole Pantoprazole Esomeprazole gastrin G CELL + Acid sensitive Yes T1/2 30-60 minutes Main elimination Enteric
More informationGastro-oesophageal reflux disease and peptic ulcer disease. By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D
Gastro-oesophageal reflux disease and peptic ulcer disease By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D Gastro-oesophageal reflux disease and peptic ulcer disease Learning objectives:
More informationSetting The setting was primary care. The economic study was carried out in Canada.
Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H-pylori-positive primary care patients with uninvestigated dyspepsia Chiba N, Van Zanten S J, Escobedo
More informationAcute Upper Gastro Intestinal (UGI) Bleeding
T Acute Upper Gastro Intestinal (UGI) Bleeding University Hospitals of Leicester NHS Trust Guidelines for Management of Acute Medical Emergencies 1. Has there been a GI bleed? There are also UHL trust
More informationTreating H. pylori in 2016
Treating H. pylori in 2016 William D. Chey, MD, FACG Professor of Medicine University of Michigan The Case: A 38 yo Russian man presents with recurrent epigastric pain which occurs after meals and sometimes
More informationWhen to Refer for OGD and the Work Up of Upper GI Malignancies
When to Refer for OGD and the Work Up of Upper GI Malignancies Dr Hong Qiantai Registrar, Department of Surgery GP Forum 27 May 2017 38 year old female, non-smoker, BMI 29 Works as investment banker Presents
More informationGASTRO-OESOPHAGEAL REFLUX DR RONALDA DELACY
GASTRO-OESOPHAGEAL REFLUX DR RONALDA DELACY DEFINITIONS GERD -Involuntary, effortless passage of gastric contents into the oesophagus +/-ejected from the mouth resulting in troublesome symptoms or complications
More informationPPIs: Good or Bad? 1. Basics of PPIs. Gastric Acid Basics. Outline. Gastric Acid Basics. Proton Pump Inhibitors (PPI)
Outline Quick basics on Proton Pump Inhibitors (PPIs) PPIs: Good or Bad? What are potential risks of PPI therapy? How to approach your patients American Gastroenterology Association (AGA) recommendations
More informationProton Pump Inhibitor De-prescribing Guidance
Amendment History Proton Pump Inhibitor De-prescribing Guidance VERSION DATE AMENDMENT HISTORY 1.0 2013 Previous version 2.0 September 2015 Comments Amendment to Flow chart and addition of Rationale page
More informationCONTROVERSIES AND ISSUES IN UPPER GASTROINTESTINAL MANAGEMENT
Roadshow report CONTROVERSIES AND ISSUES IN UPPER GASTROINTESTINAL MANAGEMENT July 2016 February 2017 Initiated, funded and developed by GI meeting report A4_V2.indd 1 Media partner 02/05/2017 15:15 Report
More informationACG and CAG Clinical Guideline: Management of Dyspepsia
988 CLINICAL GUIDELINES CME ACG and CAG Clinical Guideline: Management of Dyspepsia Paul M. Moayyedi, MB, ChB, PhD, MPH, FACG 1, Brian E. Lacy, MD, PhD, FACG 2, Christopher N. Andrews, MD 3, Robert A.
More informationUpdates in Evaluation and Management of Dyspepsia and H. Pylori Infection
Updates in Evaluation and Management of Dyspepsia and H. Pylori Infection Isabel Lee, MD Associate Professor of Health Sciences UCSF Department of Family and Community Medicine Disclosures None 2 Session
More informationSmoking cessation. Useful statistics. Smoking cessation advice. Assessing nicotine dependence
There is so much we don't know in medicine that could make a difference, and often we focus on the big things, and the little things get forgotten. To highlight some smaller but important issues, we've
More informationPharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori Taylor J L, Zagari M, Murphy K, Freston J W
Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori Taylor J L, Zagari M, Murphy K, Freston J W Record Status This is a critical abstract of an economic evaluation that
More informationNational Digestive Diseases Information Clearinghouse
Gastritis National Digestive Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What is gastritis? Gastritis is a condition in which the stomach
More informationHelicobacter pylori: Diagnosis, treatment and risks of untreated infection
Helicobacter pylori: Diagnosis, treatment and risks of untreated infection Klaus Mönkemüller Department of Gastroenterology, Hepatology und Infectius Diseases Otto-von-Guericke University, Magdeburg bb
More informationAcid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs Prof. Sheila Crowe
Acid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs 1 Division of Gastroenterology UC San Diego School of Medicine Clinical presentations of Helicobacter pylori infection
More informationUniversity Medical Center at Brackenridge. Gastroenterology Clinic Worksheet
Gastroenterology Clinic Worksheet 1. GI Bleeding (occult or symptomatic) a. CBC b. Iron, Ferritin b. Medication history 2. Iron Deficiency Anemia and no evident source (if no iron deficiency consider hematological
More informationSource of effectiveness data The effectiveness data were derived from a review and synthesis of completed studies.
Economic evaluation of maintenance therapies for reflux esophagitis: comparison between step-up therapies and step-down therapies Sugano K, Kobayashi M Record Status This is a critical abstract of an economic
More informationShoulder pain: examining the painful shoulder
There is so much we don't know in medicine that could make a difference, and often we focus on the big things, and the little things get forgotten. To highlight some smaller but important issues, we've
More informationNSAIDs Change Package 2017/2018
NSAIDs Change Package 2017/2018 Aim: To Reduce harm to patients from Non-Steroidal Anti-inflammatory Drugs (NSAIDs) in primary care Background A key aim of the Safety in Practice programme is to reduce
More informationDrug Class Monograph
Drug Class Monograph Class: Proton Pump Inhibitors Drugs: Aciphex Sprinkle (rabeprazole), Dexilant (dexlansoprazole), Lansoprazole, Nexium (esomeprazole capsule, esomeprazole granules), Omeprazole, Pantoprazole,
More informationEDUCATION PRACTICE. Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? Clinical Scenario.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1086 1090 EDUCATION PRACTICE Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? RICHARD J. SAAD* and WILLIAM D.
More informationManagement of Functional Dyspepsia (FD)
Management of Functional Dyspepsia (FD) Amy S. Oxentenko, MD, FACG Program Director and Associate Chair, IM Associate Professor of Medicine Mayo Clinic, Rochester Outline Define functional dyspepsia (FD)
More information1. The proposed strength, quantity, dosage form, dose and route of administration of the medicine including indication
Investigation 10mg 1. The proposed strength, quantity, dosage form, dose and route of administration of the medicine including indication Blister packs of 14 Solid dose form for oral administration. It
More informationPRESCRIBING SUPPORT TEAM AUDIT: Etoricoxib hypertension safety evaluation
PRESCRIBING SUPPORT TEAM AUDIT: Etoricoxib hypertension safety evaluation DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY This audit has been designed to ensure that patients
More informationFunctional Dyspepsia. Norbert Welkovics Heine van der Walt
Norbert Welkovics Heine van der Walt Characteristics: Central abdomen Pain or discomfort Not associated with bowel movements No structural or biochemical abnormalty Definition Part of Gastroduodenal disorders
More informationAn approach to dyspepsia for the pharmacist
An approach to dyspepsia for the pharmacist Ilse Truter, DCom, BPharm, MSc, PhD, Drug Utilization Research Unit (DURU) Department of Pharmacy, Nelson Mandela Metropolitan University Correspondence to:
More informationThe GP Update Handbook
The GP Update Handbook Spring / Summer 2017 www.gpcpd.com Statistics explained In the online handbook (www.gpcpd.com) you will find a simple summary of all the statistics used in this book. It s written
More informationCOMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées. Proton Pump Inhibitor Project Overview: Summaries
OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 1 March 2007 Proton Pump Inhibitor Project Overview: Summaries Supporting Informed Decisions À l appui des décisions éclairées This Executive Summary is based
More informationPrevention of Bowel Cancer: which patients do I send for colonoscopy?
Prevention of Bowel Cancer: which patients do I send for colonoscopy? Dr Chris Groves Consultant Gastroenterologist and Honorary Senior Lecturer St George s Hospital and Medical School Director, SW London
More informationPeptic Ulcer Disease Update
Peptic Ulcer Disease Update Col Pat Storms RAM 2005 Disclosure Information 84th Annual AsMA Scientific Meeting Col Patrick Storms I have no financial relationships to disclose. I will discuss the following
More informationTreatment with PPIs for Patients with GERD Symptoms
9. Treatment with PPIs for Patients with GERD Symptoms How long should you consider continuing treatment with PPIs for patients with gastroesophageal reflux disease (GERD) symptoms? Dr. H. Ayad Pinawa,
More informationProton Pump Inhibitors (PPIs) (Sherwood Employer Group)
Proton Pump Inhibitors (PPIs) (Sherwood Employer Group) BCBSKS will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6058ks-st-ippi.pdf
More informationNorthern Treatment Advisory Group
Northern Treatment Advisory Group Ferric Maltol (Feraccru ) for the treatment of iron deficiency Lead author: Daniel Hill Regional Drug & Therapeutics Centre (Newcastle) September 2018 2018 Summary Iron
More information